NPS Pharmaceuticals to Present at Upcoming Healthcare Conferences

NPS Pharmaceuticals to Present at Upcoming Healthcare Conferences

<0> NPS Pharmaceuticals, Inc.Gail Brophy, 908-450-5335 </0>

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is scheduled to present at the Lazard Capital Markets 9 Annual Healthcare Conference in New York on Wednesday, November 14, 2012 at 9:30 a.m. ET and the Jefferies 2012 Global Healthcare Conference in London Thursday, November 15, 2012 at 10:00 a.m. WET. Presentations will be available as live webcasts with replays available approximately three hours after the presentations have concluded. Interested parties may access the webcast from the investors’ calendar of events page on the NPS website at .

NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options. NPS is advancing two late-stage registration programs. A New Drug Application is undergoing FDA review for Gattex® (teduglutide) as a treatment for adults with short bowel syndrome (SBS) and a Biologic License Application is being prepared for Natpara® (rhPTH[1-84]) in adult hypoparathyroidism. NPS' earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin, and Nycomed, a Takeda company.

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.